Tags

Type your tag names separated by a space and hit enter

Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma.
Ann Allergy Asthma Immunol. 2003 Jun; 90(6):583-91; quiz 591-2, 659.AA

Abstract

LEARNING OBJECTIVES

To review the rationale supporting the use of levalbuterol [(R)-albuterol] for the treatment of pediatric and adult asthma.

DATA SOURCES

Peer-reviewed articles, selected abstracts from studies presented at recent professional meetings, and the Xopenex [levalbuterol, (R)-albuterol; Sepracor, Marlborough, MA] Summary Basis of Approval and package insert.

STUDY SELECTION

Institutional review board-approved clinical study protocols.

RESULTS

Levalbuterol is a single isomer beta2-agonist that differs from racemic albuterol by elimination of (S)-albuterol. Levalbuterol is an effective bronchodilator whose primary mechanism of action is unimpeded by (S)-albuterol. Thus, when compared with racemic albuterol, clinically comparable bronchodilation can be achieved with doses that substantially lessen beta-mediated side effects. In chronic or acute treatment of asthma, this favorable therapeutic profile cannot apparently be duplicated by increasing or decreasing the dose of racemic albuterol or by the addition of anticholinergic agents such as ipratropium bromide.

CONCLUSIONS

Levalbuterol seems to provide efficacy and safety advantages in pediatric and adult patients suffering from asthma. Its use may afford a cost benefit as well. More clinical studies are required to extend these observations for use in the treatment of other pulmonary diseases in both adults and children and to determine levalbuterol's impact on long-term therapy of respiratory diseases.

Authors+Show Affiliations

Southern California Research, Mission Viejo, California 92691, USA. weberger@uci.edu

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

12839314

Citation

Berger, William E.. "Levalbuterol: Pharmacologic Properties and Use in the Treatment of Pediatric and Adult Asthma." Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, vol. 90, no. 6, 2003, pp. 583-91; quiz 591-2, 659.
Berger WE. Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma. Ann Allergy Asthma Immunol. 2003;90(6):583-91; quiz 591-2, 659.
Berger, W. E. (2003). Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma. Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, 90(6), 583-91; quiz 591-2, 659.
Berger WE. Levalbuterol: Pharmacologic Properties and Use in the Treatment of Pediatric and Adult Asthma. Ann Allergy Asthma Immunol. 2003;90(6):583-91; quiz 591-2, 659. PubMed PMID: 12839314.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma. A1 - Berger,William E, PY - 2003/7/4/pubmed PY - 2003/8/9/medline PY - 2003/7/4/entrez SP - 583-91; quiz 591-2, 659 JF - Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology JO - Ann. Allergy Asthma Immunol. VL - 90 IS - 6 N2 - LEARNING OBJECTIVES: To review the rationale supporting the use of levalbuterol [(R)-albuterol] for the treatment of pediatric and adult asthma. DATA SOURCES: Peer-reviewed articles, selected abstracts from studies presented at recent professional meetings, and the Xopenex [levalbuterol, (R)-albuterol; Sepracor, Marlborough, MA] Summary Basis of Approval and package insert. STUDY SELECTION: Institutional review board-approved clinical study protocols. RESULTS: Levalbuterol is a single isomer beta2-agonist that differs from racemic albuterol by elimination of (S)-albuterol. Levalbuterol is an effective bronchodilator whose primary mechanism of action is unimpeded by (S)-albuterol. Thus, when compared with racemic albuterol, clinically comparable bronchodilation can be achieved with doses that substantially lessen beta-mediated side effects. In chronic or acute treatment of asthma, this favorable therapeutic profile cannot apparently be duplicated by increasing or decreasing the dose of racemic albuterol or by the addition of anticholinergic agents such as ipratropium bromide. CONCLUSIONS: Levalbuterol seems to provide efficacy and safety advantages in pediatric and adult patients suffering from asthma. Its use may afford a cost benefit as well. More clinical studies are required to extend these observations for use in the treatment of other pulmonary diseases in both adults and children and to determine levalbuterol's impact on long-term therapy of respiratory diseases. SN - 1081-1206 UR - https://www.unboundmedicine.com/medline/citation/12839314/Levalbuterol:_pharmacologic_properties_and_use_in_the_treatment_of_pediatric_and_adult_asthma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1081-1206(10)61859-5 DB - PRIME DP - Unbound Medicine ER -